BC Extra | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

Roche's Gazyva clears Phase II hurdle in lupus nephritis  Gazyva obinutuzumab from Roche (SIX:ROG; OTCQX:RHHBY) met the primary endpoint in the Phase II NOBILITY trial to treat lupus nephritis. Given in combination with standard of...
BC Week In Review | Nov 9, 2018
Clinical News

Bone stops Phase III of Preob cells in osteonecrosis for futility

Bone Therapeutics S.A. (Euronext:BOTHE) discontinued a Phase III trial of its Preob cells to treat osteonecrosis of the hip after an interim 12-month analysis by a DSMB showed that the trial was unlikely to meet...
BC Week In Review | Oct 27, 2017
Clinical News

Bone's Allob meets in Phase I/IIa for delayed-union bone fractures

In September, Bone Therapeutics S.A. (Euronext:BOTHE) reported interim data from a Phase I/IIa trial in 16 patients with delayed-union fractures of long bones showing that Allob met the primary endpoint of improving radiological Tomographic Union...
BC Week In Review | Oct 24, 2016
Clinical News

Allob: Additional Phase IIa data

Additional data from 8 patients with symptomatic degenerative lumbar disc disease that required interbody fusion in an open-label, Belgian Phase IIa trial showed that a single implantation of Allob mixed with bioceramic granules into the...
BC Week In Review | May 9, 2016
Clinical News

Allob: Completed Phase IIa enrollment

Bone Therapeutics completed enrollment of 18 patients in an open-label, Belgian Phase IIa trial evaluating a single implantation of Allob mixed with bioceramic granules. The study enrolled patients with symptomatic degenerative lumbar disc disease that...
BC Week In Review | Mar 7, 2016
Clinical News

Allob: Phase IIa data

Data from the first patient with symptomatic degenerative lumbar disc disease that required interbody fusion in an open-label, Belgian Phase IIa trial showed that a single implantation of Allob mixed with bioceramic granules into the...
BC Extra | Feb 5, 2015
Financial News

Bone Therapeutics raises EUR 32.2M in IPO

Regenerative medicine play Bone Therapeutics S.A. (Euronext:BOTHE) raised EUR 32.2 million ($36.5 million) through the sale of 2 million shares at EUR 16 in an IPO, giving it a market cap of EUR 104.8 million...
BC Week In Review | Feb 2, 2015
Clinical News

Allob: Phase I/IIa data

Data from the first cohort of 4 patients with non-infected, delayed-union fractures of long bones in an open-label, European Phase I/IIa trial showed that a single implantation of Allob into the fracture site led to...
BC Week In Review | Sep 29, 2014
Clinical News

Allob: Phase IIa started

Bone Therapeutics began an open-label, Belgian Phase IIa trial to evaluate a single dose of Allob mixed with bioceramic granules in about 16 patients with symptomatic degenerative lumbar disc disease that requires interbody fusion. Allob...
BC Week In Review | Jul 14, 2014
Clinical News

Allob: Phase I/IIa started

Bone Therapeutics began an open-label, European Phase I/IIa trial to evaluate a single implantation of Allob in 32 patients with non-infected, delayed-union fractures of long bones. A delayed-union fracture is defined as absence of healing...
Items per page:
1 - 10 of 10